Table.

MAP (mm Hg) of Glaucomatous Rats Treated With DIZE or Left Untreated

	Nontreated Animals	Treated Animals
Preventive and systemic protocol, n = 8
Wk 0	119.5 ± 7.5	120.5 ± 6.7
Wk 1	128.5 ± 4.1	123.4 ± 2.2
Wk 2	122.0 ± 5.6	113.0 ± 5.1
Wk 3	118.4 ± 3.5	119.5 ± 4.5
Wk 4	125.3 ± 4. 9	126.8 ± 3.9
Preventive and topical eye drops protocol, n = 7–8
Wk 0	117.0 ± 1.2	118.6 ± 3.8
Wk 1	117.4 ± 2.5	119.4 ± 4.7
Wk 2	116.4 ± 4.7	117.6 ± 6.1
Wk 3	118.2 ± 4.9	120.4 ± 3.9
Wk 4	116.2 ± 1.8	119.2 ± 2.6
Treatment and topical eye drops protocol, n = 7
Wk 0	117.3 ± 6.7	122.6 ± 2.1
Wk 1	128.0 ± 4.1	131.0 ± 5.3
Wk 2	127.5 ± 3.8	121.6 ± 7.0
Wk 3	127.3 ± 6.4	131.0 ± 4.8

No significant differences were observed between the groups during the treatment period (two-way ANOVA followed by the Bonferroni posttest).